Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis To Take Back Lamisil Chinese Rights From GSK

This article was originally published in PharmAsia News

Executive Summary

The seven-year itch has struck the successful partnership between Novartis and GlaxoSmithKline. In 2001, GSK's subsidiary in China TSKF secured the rights to develop Lamisil (terbinafine) tablet from Novartis, as well as to produce and sell Lamisil cream. GSK was able to expand the drug's market share in the country rapidly from 2 percent to 12 percent. However, Novartis recently confirmed that it has granted exclusive selling rights for the tablet in China to Profex, a dermatology products company based in Shanghai. Novartis has been strengthening its OTC sector and one priority is to get back itsLamisil cream. GSK is not surrendering the product immediately; meanwhile, it is sparing no effort in promoting its own dermatology drug Bactroban (mupirocin). (Click here for more - Chinese Language)

You may also be interested in...



Catchup Capsule: Key APAC Insights You Need To Read

Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.

QUOTED. 4 December. Eric Borin.

Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.

Pfizer’s Expected 2020 COVID-19 Vaccine Production Fell By 50% After Scaleup Delays

Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel